Synthena AG
Oligonucleotide based therapeutics
Synthena is developing oligonucleotide based therapeutics primarily for the treatment of genetic neuromuscular diseases by using its tricyclo-DNA molecular platform.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
No news
No milestones
No Jobs
No videos and documents
